花旗研究报告指出，经过一段时间暂停评级后，重新予荣昌生物(09995.HK) “买入/高风险”评级，目标价为105港元。因集团与AbbVie就PD-1/VEGF选药物RC148达成合作，进一步拓展其管线候选药物的全球潜力。花旗认为，合作完成后，市场焦点应转移至基于临床数据和竞争格局的未来全球三期临床研究及商业化潜力。关于泰它西普的全球开发，其治疗全身型重症肌无力的三期临床研究顶线数据或于2027年...
Source Link花旗研究报告指出，经过一段时间暂停评级后，重新予荣昌生物(09995.HK) “买入/高风险”评级，目标价为105港元。因集团与AbbVie就PD-1/VEGF选药物RC148达成合作，进一步拓展其管线候选药物的全球潜力。花旗认为，合作完成后，市场焦点应转移至基于临床数据和竞争格局的未来全球三期临床研究及商业化潜力。关于泰它西普的全球开发，其治疗全身型重症肌无力的三期临床研究顶线数据或于2027年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.